Business Description
Annexin Pharmaceuticals AB
ISIN : SE0025159387
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
ANNX.SwedenQ910.Germany IPO Date
2023-10-30Description
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.72 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 28.7 | |||||
3-Year EPS without NRI Growth Rate | 28.9 | |||||
3-Year FCF Growth Rate | 28.9 | |||||
3-Year Book Growth Rate | -31.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.95 | |||||
9-Day RSI | 59.72 | |||||
14-Day RSI | 53.34 | |||||
3-1 Month Momentum % | 7.52 | |||||
6-1 Month Momentum % | -31.74 | |||||
12-1 Month Momentum % | -50.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.31 | |||||
Quick Ratio | 3.31 | |||||
Cash Ratio | 3.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.2 | |||||
Shareholder Yield % | -12.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -120.95 | |||||
ROA % | -105.58 | |||||
ROIC % | -1002.14 | |||||
3-Year ROIIC % | -182.33 | |||||
ROC (Joel Greenblatt) % | -3699.8 | |||||
ROCE % | -123.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.46 | |||||
Price-to-Tangible-Book | 6.44 | |||||
EV-to-EBIT | -1.89 | |||||
EV-to-EBITDA | -1.89 | |||||
EV-to-FCF | -1.95 | |||||
| Price-to-Net-Current-Asset-Value | 7.25 | |||||
| Price-to-Net-Cash | 8.29 | |||||
Earnings Yield (Greenblatt) % | -52.91 | |||||
FCF Yield % | -41.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Annexin Pharmaceuticals AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.54 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 47.84 | ||
| 14-Day RSI | 53.34 | ||
| 14-Day ATR (€) | 0.03095 | ||
| 20-Day SMA (€) | 1.111889 | ||
| 12-1 Month Momentum % | -50.61 | ||
| 52-Week Range (€) | 1.03 - 2.802415 | ||
| Shares Outstanding (Mil) | 7.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Annexin Pharmaceuticals AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Annexin Pharmaceuticals AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-23 | In 110 days | ||
| Second quarter earnings results for 2026 | 2026-07-17 | In 12 days | ||
| General meeting for 2026 | 2026-05-15 | 1.38 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 1.33 (+0.00%) | ||
| Annual report for 2025 | 2026-03-23 | 1.30 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-05 | 1.29 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-23 | 2.31 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-07-17 | 2.64 (+0.00%) | ||
| 0.01:1 Stock Split | 2025-05-28 | 2.47 (+0.00%) | ||
| General meeting for 2025 | 2025-05-15 | 1.44 (+0.00%) |
Show
Entries
Annexin Pharmaceuticals AB Frequently Asked Questions
What is Annexin Pharmaceuticals AB(FRA:Q910)'s stock price today?
The current price of FRA:Q910 is €1.16. The 52 week high of FRA:Q910 is €2.80 and 52 week low is €1.03.
When is next earnings date of Annexin Pharmaceuticals AB(FRA:Q910)?
The next earnings date of Annexin Pharmaceuticals AB(FRA:Q910) is 2026-07-17 Est..
Does Annexin Pharmaceuticals AB(FRA:Q910) pay dividends? If so, how much?
Annexin Pharmaceuticals AB(FRA:Q910) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| First patient treated in the second dose group in Annexin's RVO study | 2023-10-25 | ||
| Annexin announces success in the company's cancer initiative | 2023-09-29 | ||
| Promising signals of effect in Annexin's RVO-study | 2023-08-11 |
Articles on Annexin Pharmaceuticals AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers